Authors: Qingxia Guan Shuang Sun Xiuyan Li Shaowa Lv Ting Xu Jialin Sun Wenjing Feng Liang Zhang Yongji Li
Publish Date: 2015/12/24
Volume: 27, Issue: 2, Pages: 24-
Abstract
This study investigated the therapeutic efficiency of monomethoxy polyethylene glycolpolylacticcoglycolic acid mPEGPLGA coloaded with syringopicroside and hydroxytyrosol as a drug with effective targeting and loading capacity as well as persistent circulation in vivo The nanoparticles were prepared using a nanoprecipitation method with mPEGPLGA as nanocarrier coloaded with syringopicroside and hydroxytyrosol SHNPs The parameters like in vivo pharmacokinetics biodistribution in vivo fluorescence in vivo endomicroscopy and cellular uptake of SHNPs were investigated Results showed that the total encapsulation efficiency was 3238 ± 276 Total drug loading was 1201 ± 042 particle size was 9170 ± 211 nm polydispersity index was 022 ± 001 and zeta potential was −245 ± 116 mV for the optimized SHNPs The nanoparticle morphology was characterized using transmission electron microscopy which indicated that the particles of SHNPs were in uniformity within the nanosize range and of spherical core shell morphology Drug release followed Higuchi kinetics Compared with syringopicroside and hydroxytyrosol mixture SH SHNPs produced drug concentrations that persisted for a significantly longer time in plasma following secondorder kinetics The nanoparticles moved gradually into the cell thereby increasing the quantity ALT AST and MDA levels were significantly lower on exposure to SHNPs than in controls SHNPs could inhibit the proliferation of HepG2215 cells and could be taken up by HepG2215 cells The results confirmed that syringopicroside and hydroxytyrosol can be loaded simultaneously into mPEGPLGA nanoparticles Using mPEGPLGA as nanocarrier sustained release high distribution in the liver and protective effects against hepatic injury were observed in comparison to SH
Keywords: